申请人:TAISHO PHARMACEUTICAL CO. LTD
公开号:EP0795545A1
公开(公告)日:1997-09-17
A pyridine derivative represented by the following formula:
, where R1 is a methyl group or a functional group represented by any one of the following formulae:
―CONHCH2CH2N(CH3)2
―CONHCH2CH2CH2N(CH3)2
―COOCH2CH2N(CH3)2
―COOCH2CH2N(CH2CH3)2
―NHCOCH2N(CH3)2
―NHCOCH2N(CH2CH3)2
and R2 is a hydrogen atom, an amino group or a functional group represented by any one of the following formulae:
―CONHCH2CH2N(CH3)2
―COOCH2CH2N(CH3)2
―NHCOCH2N(CH3)2
―NHCOCH2N(CH2CH3)2
or a salt thereof directly or indirectly acts on neuronal cells in vivo and is expected to show an effect on amelioration and curing of nerve disorders due to neuronal degeneration, with application as a drug for ameliorating and curing, for example, traumatic symptoms and maladies, those induced by drugs such as alcohol, antineoplastic agents, etc., inflammatory ones, metabolic ones as observed in diabetes, etc., and furthermore those due to idiopathic degeneration of peripheral nerves, and also with application as drugs for ameliorating and curing symptoms and maladies due to degeneration of central nerves, for example, Alzheimer's disease and cerebrovascular ischemia, Down syndrome, Parkinson's disease, Huntington chorea, diseases secondary to cerebral ischemia, cerebral infarction, intracerebral bleeding, head injuries, etc., amnesia, spinal neuropathy, etc.
下式所代表的吡啶衍生物:
其中 R1 是甲基或下式中任何一种所代表的官能团:
-conhch2ch2n(ch3)2
-conhch2ch2ch2n(ch3)2
-cooch2ch2n(ch3)2
-cooch2ch2n(ch2ch3)2
-NHCOCH2N(CH3)2
-NHCOCH2N(CH2CH3)2
而 R2 是氢原子、氨基或由下式中任一式代表的官能团:
-conhch2ch2n(ch3)2
-cooch2ch2n(ch3)2
-NHCOCH2N(CH3)2
-NHCOCH2N(CH2CH3)2
或其盐在体内直接或间接作用于神经元细胞,并有望显示出改善和治疗因神经元变性引起的神经紊乱的效果,可用作改善和治疗创伤性症状和弊病、酒精等药物引起的症状和弊病、抗肿瘤药物等引起的症状和弊病、炎症性症状和弊病、糖尿病等引起的代谢性症状和弊病的药物、此外,还可用于改善和治疗中枢神经退化引起的症状和疾病,如阿尔茨海默病和脑血管缺血、唐氏综合症、帕金森病、亨廷顿舞蹈症、继发于脑缺血、脑梗塞、脑出血、头部损伤等的疾病、健忘症、脊髓神经病等。